# A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

> **NCT05185843** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome

## Interventions

- **DRUG:** Olezarsen

## Key facts

- **NCT ID:** NCT05185843
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-25
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185843, "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05185843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*